A Study of Ivonescimab in First-Line ES-SCLC
A phase 2 trial of Ivonescimab, Cadonilimab, AK117 in small-cell lung cancer, run by Akeso, now recruiting.
Overview
A Study of Ivonescimab in First-Line ES-SCLC is a phase 2 interventional study registered as NCT07245446 by Akeso, with 180 participants planned, started 2025-10-29 and due to reach its primary completion in 2027-12. Interventions recorded: Ivonescimab, Cadonilimab, AK117, Etoposide, Carboplatin (AUC 5). Conditions listed: Extensive-stage Small Cell Lung Cancer (ES-SCLC). No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialAK112 and AK104 With or Without Chemotherapy in Advanced Non-small Cell Lung Cancer
Shares Cadonilimab, Ivonescimab, Akeso, Carboplatin.
- TrialA Study of AK138D1 Alone or in Combination With Ivonescimab in Advanced Non-Small Cell Lung Cancer
Shares Ivonescimab, Akeso, Carboplatin, Small-cell lung cancer.
- TrialAn Exploratory, Multi-cohort Phase II Study of Combination Therapy With AK104 and AK112 for Recurrent Ovarian Cancer
Shares Cadonilimab, Ivonescimab, Akeso.
- TrialAK112 in Combination With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer
Shares Ivonescimab, Akeso, Carboplatin, Small-cell lung cancer.
- TrialA Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemor
Shares Ivonescimab, Akeso, Small-cell lung cancer.
- TrialAK112 Neoadjuvant/Adjuvant Treatment for Resectable NSCLC
Shares Ivonescimab, Akeso, Carboplatin, Small-cell lung cancer.
- TrialA Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC)
Shares Cadonilimab, Ivonescimab, Akeso.
- TrialAK112 and Cadonilimab Combined With Chemotherapy for 1L Treatment of Metastatic Pancreatic Cancer
Shares Cadonilimab, Ivonescimab, Akeso.